Share on StockTwits

Alcobra (NASDAQ:ADHD) is scheduled to be issuing its quarterly earnings data on Monday, August 11th. Parties that wish to listen to the company’s conference call can do so using this link.

Alcobra (NASDAQ:ADHD) last issued its quarterly earnings data on Thursday, May 15th. The company reported ($0.57) earnings per share for the quarter.

Shares of Alcobra (NASDAQ:ADHD) opened at 19.46 on Friday. Alcobra has a one year low of $11.49 and a one year high of $26.96. The stock’s 50-day moving average is $18. and its 200-day moving average is $18.95. The company’s market cap is $265.4 million.

A number of analysts have recently weighed in on ADHD shares. Analysts at Piper Jaffray initiated coverage on shares of Alcobra in a research note on Monday. They set an “overweight” rating and a $42.00 price target on the stock. On a related note, analysts at Roth Capital initiated coverage on shares of Alcobra in a research note on Friday, August 1st. They set a “buy” rating and a $40.00 price target on the stock. Finally, analysts at WBB Securities initiated coverage on shares of Alcobra in a research note on Thursday, June 26th. They set a “hold” rating and a $18.00 price target on the stock. One investment analyst has rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $33.83.

Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (NASDAQ:ADHD), a common and morbid neuropsychiatric condition in children and adults.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.